<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14857">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01773408</url>
  </required_header>
  <id_info>
    <org_study_id>NP28679</org_study_id>
    <secondary_id>2012-004882-41</secondary_id>
    <nct_id>NCT01773408</nct_id>
  </id_info>
  <brief_title>A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia</brief_title>
  <official_title>A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/IB, open-label study will evaluate the safety and pharmacokinetics of
      escalating doses of RO5503781 as single agent or in combination with cytarabine in patients
      with acute myelogenous leukemia. An optional Part 3 in which RO5503781 is administered with
      cytarabine and anthracycline may be considered.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>approximately 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>approximately 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Complete remission</measure>
    <time_frame>approximately 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Partial Response</measure>
    <time_frame>approximately 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Disease progression</measure>
    <time_frame>approximately 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma concentrations of RO5503781 alone and in combination with cytarabine</measure>
    <time_frame>first 28-day cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Leukemia-related biomarkers</measure>
    <time_frame>first 28-day cycle</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Hematologic malignancy response</measure>
    <time_frame>approximately 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Myelogenous Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>Part 1: RO5503781</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: RO5503781 + Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: RO5503781 + Cytarabine + Anthracycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5503781</intervention_name>
    <description>multiple escalating doses</description>
    <arm_group_label>Part 1: RO5503781</arm_group_label>
    <arm_group_label>Part 2: RO5503781 + Cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>1000 mg/m2 iv daily for 6 days each cycle</description>
    <arm_group_label>Part 2: RO5503781 + Cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anthracycline</intervention_name>
    <description>Antracycline per standard clinical practice</description>
    <arm_group_label>Part 1: RO5503781</arm_group_label>
    <arm_group_label>Part 2: RO5503781 + Cytarabine</arm_group_label>
    <arm_group_label>Part 3: RO5503781 + Cytarabine + Anthracycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Documented/confirmed acute myelogenous leukemia (AML), except for acute promyelocytic
             leukemia

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 in Part 1 and
             Part 2, patients enrolled in the extension/tail portion must have an ECOG performance
             status of 0 or 1

          -  All non-hematological adverse events of any prior chemotherapy, surgery or
             radiotherapy must have resolved to NCI-CTCAE Grade &lt;/=2 prior to starting therapy

          -  Adequate hepatic and renal function

          -  Willing to submit the blood sampling and bone marrow sampling required by protocol
             Additional inclusion criteria for Parts 1-3 may apply.

        Exclusion Criteria:

          -  Patients receiving any other investigational or commercial agents or therapies
             administered with the intention to treat their malignancy within 14 days of first
             receipt of study drug, with the exception of hydroxyurea as defined in protocol

          -  History of allergic or toxic reactions attributed to cytarabine (Part 2) or history
             of allergic reactions to components of the formulated product

          -  Current evidence of central nervous system (CNS) leukemia

          -  Patients with severe and/or uncontrolled medical conditions or other conditions that
             could affect their participation in the study

          -  Patients with evidence of electrolyte imbalance of Grade &gt;/= 2 which cannot be
             corrected prior to study initiation

          -  Pregnant or breastfeeding women

          -  HIV-positive patients receiving anti-retroviral therapy

          -  Patients who refuse to potentially receive blood products and/or have a
             hypersensitivity to blood products Additional exclusion criteria for Parts 1-3 may
             apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: NP28679 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
